Last reviewed · How we verify
Glargine Basal-Bolus Therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Glargine Basal-Bolus Therapy (Glargine Basal-Bolus Therapy) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glargine Basal-Bolus Therapy TARGET | Glargine Basal-Bolus Therapy | Eli Lilly and Company | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glargine Basal-Bolus Therapy CI watch — RSS
- Glargine Basal-Bolus Therapy CI watch — Atom
- Glargine Basal-Bolus Therapy CI watch — JSON
- Glargine Basal-Bolus Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Glargine Basal-Bolus Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/glargine-basal-bolus-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab